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Introduction 
 
Chronic hypertension (CHT) is defined as blood pressure (BP) ≥140/90mmHg 
that precedes the pregnancy or is detected <20 weeks gestation [1]. It is a 
common medical condition that currently affects approximately 3% of 
pregnancies [2]. This percentage is likely to increase with increasing maternal 
age and body mass index (BMI) within the population. Pregnancies 
complicated by CHT are at increased risk of adverse maternal and fetal 
outcomes including: superimposed preeclampsia, iatrogenic pre-term delivery 
and fetal growth restriction (FGR) [3].  
 
Optimal treatment of hypertension in pregnancy remains controversial. 
Although treating hypertension has been shown to reduce the incidence of 
severe hypertension by 50% this has not been associated with an 
improvement in other outcomes such as a reduced risk of pre-eclampsia (PE), 
FGR or neonatal mortality [4]. Concerns regarding the over treatment of 
hypertension were raised in a systematic review that reported an association 
between a reduction in mean arterial pressure (MAP) by 10mmHg and a 
decrease in birthweight of 176g [5]. To try to address these issues Magee et 
al. conducted a large randomized control trial (RCT) investigating whether 
tight or less tight BP control was associated with better outcomes [6]. The 
findings of the CHIPS trial have shown that aiming for a target diastolic blood 
pressure (DBP) of 85mmHg compared with 100mmHg was associated with 
maternal benefits without detrimental effect on perinatal outcome [6]. 
 
The range of anti-hypertensive agents available for use in pregnancy is limited 
due to a lack of safety data on potential teratogenic or fetotoxic effects. 
Methyldopa had been the drug of choice as a result of many years of use [7]. 
There are limited head to head studies comparing different antihypertensive 
agents for the treatment of CHT in pregnancy [8]. Currently the National 
Institute of Health Care Excellence (NICE) recommends labetalol as the first 
line drug in the UK for the treatment of CHT [9], with nifedipine and 
methyldopa as alternative options.  
 
  
Physiological adaptations to pregnancy alter drug pharmacokinetics. Available 
data regarding the pharmacokinetics and pharmacodynamics of labetalol and 
nifedipine in pregnancy are limited; existing studies had small sample sizes 
and investigated effects in the third trimester only. However, for both drugs 
clearance appears to be increased in pregnancy [10]. To date there are no 
studies investigating and comparing the acute BP lowering effects of 
antihypertensive medication in pregnancy. The optimal drug, dose and dosing 
interval required to achieve the desired BP targets remains uncertain and 
variation exists in prescribing regimes due to a paucity of evidence based 
guidelines. 
 
Nifedipine as a modified release (MR) preparation and labetalol are two of the 
most commonly prescribed antihypertensive agents in pregnancy. The 
primary aim of this exploratory study was to describe and compare the BP 
lowering effects of these two medications on the systolic BP (SBP) and DBP 
in pregnancies complicated by CHT. We also investigated the effect of each 
drug on heart rate (HR) and determined whether the use of labetalol or 
nifedipine resulted in better overall BP control by analysing the time spent in 
target. 
 
  
  
Methods 
 
Recruitment 
We performed a single centre exploratory study at a tertiary maternity 
hospital. Women were recruited from the Manchester Antenatal Vascular 
Services (MAViS) clinic, which is a dedicated research clinic for pregnant 
women with pre-existing vascular disease. Women who were on a stable 
dose of labetalol or nifedipine MR for at least 1 week, with a diagnosis of CHT 
were offered 24-hour ambulatory blood pressure monitoring (ABPM). 
Participants were fitted with a SpaceLabs monitor and advised to continue 
with normal daily activities. BP readings were not revealed to the woman 
during the monitoring period. The BP was recorded every 30 minutes during 
the day (08:00-22:00h) and hourly at night (22:00-08:00h). Drug ingestion 
time, sleep and wake periods were self-reported. Baseline demographics 
were recorded.  
 
Statistical methods 
 
Initial Data Analysis 
Patient demographics were compared and analysed using chi-squared test. 
The pre-dose levels of SBP and DBP were compared between each 
treatment using boxplots. The correlation between pre-dose SBP and DBP 
with dose and gestation, were first explored graphically before being 
assessed via a one-way ANOVA analysis. The time-series of SBP, DBP and 
HR were binned in the following way to assess temporal trends. The pre-dose 
recording was assigned to the first bin. The second, third, fourth and fifth bins 
contained the first quartile (minus pre-dose values), second, third and fourth 
quartile of the data over the dosing interval. Due to the varying dosing 
regimes, time series data is available for 6.4-12.5 hours for labetalol and 8.5-
16.4 hours for nifedipine.  For each bin a boxplot was created and all boxplots 
were plotted in chronological order. Only daytime BP and HR readings were 
used.     
  
  
Time-series structural model 
An indirect response model was used to analyse the SBP, DBP and HR time-
series. A schematic of the model together with example simulations can be 
seen in the Supplementary Material. 
 
Time-series data analysis 
The time-series under consideration contains two levels of hierarchy and thus 
two sources of variability; between patient and within patient (inter-visit). To 
account for these sources of variability the structural models described above 
were placed within a mixed-effects framework and analysed in the following 
way.  
 
For SBP and DBP, the drugs are intended to lower these values and so the 
inhibitory model was used.  For HR we considered both the inhibitory and 
stimulatory model given that the HR can produce the opposite dynamics to 
that seen for SBP and DBP. For the SBP and DBP analysis the goodness of 
fit statistic, -2xlog-likelihood(-2LL), was calculated for the pooled data-set 
(labetalol and nifedipine) using a step-wise approach. Firstly, without 
accounting for which visit belonged to which woman, secondly, accounting for 
visit-to-visit correlations and finally accounting for which drug a woman was 
prescribed. Finally, where a treatment effect was identified gestation time 
effect was explored through inclusion of an interaction term (drug and 
gestation). The likelihood ratio test was used to assess the improvement in 
model fit after including each piece of extra information.  
 
  
  
For the HR analysis we fitted both the inhibitory and stimulatory models to 
each drug data-set separately, firstly, without accounting for which visit 
belonged to which woman. The choice of which model to take forward for 
further analysis was based on certain parameter conditions to ensure the 
correct dynamics for the given model, see Supplementary Material.  If the 
inhibitory model was found to give the best fit for one drug and the stimulatory 
model for the other then the data was kept un-pooled. Hence, in that situation 
only an assessment of which visit belonged to which woman was performed. 
Analysis of the effect of gestation time was modelled in the same way as for 
SBP and DBP analysis if a pooled data-set was used via an interaction term 
between drug and gestation.  However, if the data was kept un-pooled then 
gestation was modelled as an additive covariate. 
 
Further details on parameter estimates with 95% confidence intervals (CI) and 
model diagnostic plots for the final models can be found in the supplementary 
material. R v3.1.1 was used for all analyses conducted.  
 
Simulation of time in target: SBP and DBP 
The parameter estimates for each woman from the final models were used to 
simulate SBP and DBP time-series for eight hours. This time-series was then 
used to calculate the average proportion of time spent in target for each 
patient during all visits. The following cut offs were used as targets: SBP 
<140mmHg and DBP 80-99mmHg. To assess the quantitative difference in 
the distribution of the proportion of time spent in target between each drug for 
SBP and DBP p-values from the Kolmogorov-Smirnov test were calculated.    
  
  
Results 
 
Study Participants 
A total of 48 women underwent ABPM; 24 on labetalol and 24 on nifedipine 
MR. Table 1 presents the characteristics and delivery outcomes of the two 
groups. The majority of women had a diagnosis of essential hypertension 
(65%). There was no significant difference between the two groups with 
respect to ethnicity, BMI, gestation and underlying diagnosis. Labetalol was 
most commonly prescribed as an 8-hourly regime and there were nine 
different total daily doses. Nifedipine MR was predominantly prescribed 12-
hourly and there were eight different total daily doses. Delivery outcomes 
were compared. Adverse outcomes were classified as: PE, isolated FGR 
(customised birth-weight <10th centile) or other. The only statistically 
significant difference was the number of vaginal deliveries achieved.  
 
 Labetalol n=24 Nifedipine n=24 P value 
Ethnicity   0.07 
White European 14 (58%) 9 (37%)  
African/Caribbean 7 (29%) 5 (21%)  
Other 3 (13%) 10 (42%)  
BMI at booking (kg/m
2
) 32 ± 7 29 ± 6 0.18 
Gestation at ABPM monitoring 
(weeks) 
22.2 ± 6.9 23.2 ± 7.5 0.65 
Diagnosis    0.11 
Essential HTN 18 (75%) 13 (54%)  
Renal HTN 6 (25%) 10 (42%)  
Other 0 (0%) 1 (4%)  
Total dose mg/ day 
(median/IQR) 
400 (225, 600) 40 (20, 60)  
Women on b.d. dose 8 (33%) 22 (92%)  
Delivery Outcome    
Delivery gestation (weeks)  37.9 (36.7,38.4) 37.6 (35.4, 38.6) 0.82 
Vaginal delivery 12 (50%) 10 (42%) 0.02 
Birth weight centile 33 (31) 30 (34) 0.78 
Complication 11 (46%) 17 (71%) 0.85 
 
Table 1. Patient demographics and delivery outcome presented as either mean ± sd, N (%) or 
median (IQR) 
  
  
Initial Data Analysis 
Pre-dose SBP and DBP were compared between the two treatment groups 
and there was no significant difference in baseline SBP or DBP  (p=0.922 and 
p=0.805 respectively). 
 
The relationship between the pre-dose SBP and DBP values and the dose 
taken for the two treatments or gestation was assessed (Figure 1). In this 
cohort of women no effect of gestation was seen the on the pre-dose SBP or 
DBP. We did however find a statistically significant relationship between pre-
dose BP and the dose of nifedipine, with the most hypertensive women 
scheduled to take the highest doses of nifedipine (p=0.002); this relationship 
was not significant for women taking labetalol.  
  
 
 
p-value = 0.710 p-value = 0.423 
p-value = 0.056 p-value = 0.091 
E) F) 
G) H) 
p-value = 0.002 
p-value = 0.002 
p-value = 0.196 p-value =  0.454 
A) B) 
C) D) 
  
 
Figure 1. Panels A and B show a significant trend between the dose of nifedipine and pre-
dose SBP and DBP values (p=0.002 for both). The plots in panels C and D demonstrate that 
there was no correlation for nifedipine between gestation at monitoring and the pre-dose SBP 
and DBP values (p=0.454 and p=0.196 respectively). Panels E and F show no trend between 
the dose of labetalol and pre-dose SBP and DBP values (p=0.710 and p=0.423 respectively). 
The plots in panels G and H show a lack of correlation for labetalol between gestation and 
pre-dose SBP and DBP values (p=0.091 and p=0.056 respectively). 
 
Time Series Data 
Figure 2 shows the binned time series data. 
 
SBP and DBP  
Blood pressure readings post-dose were grouped into quartiles that 
correspond to the following time frames: 0-2.5, 2.5-4, 4-6.4 and 6.4 - 12.5 
hours for labetalol and 0-3, 3-5.7, 5.7-8.5 and 8.5-16.4 hours for nifedipine. 
For labetalol there appeared to be a BP lowering effect within 2.5 hours of 
drug ingestion on both the SBP and DBP; this effect was short lasting. A 
similar trend was not seen for nifedipine. 
 
HR 
Data was binned into the same quartiles as for SBP and DBP. No strong trend 
similar to that seen for BP after labetalol or nifedipine treatment was 
observed, however there did appear to be opposite effects; a reduction in HR 
with labetalol and a rise with nifedipine. 
 
 
 
  
 
 
 
Figure 2. Boxplots of the binned time-series data for pre-dose baseline values and 
subsequent time quartiles for SBP, DBP and HR. The box shows the inter-quartile range with 
the solid horizontal line within the box the median. 
  
  
Time Series Data Analysis 
The trends, described above, were further assessed using the indirect 
response model. The raw data and model mean fit are shown in figure 3. 
These data show a modest difference between the drug effects on both the 
SBP and DBP time-series (p=0.014). For HR we found that the dynamics 
were different qualitatively between the two drugs; a stimulatory effect was 
found for nifedipine and an inhibitory one for labetalol.   
 
 
 
Figure 3. SBP, DBP and HR values for labetalol (red open circles) and nifedipine (black open 
circles) after a single dose together with the mean simulation (solid lines).  
  
Having established that a treatment effect existed on the SBP, DBP and HR 
time-series data, we next evaluated whether this effect was modulated by the 
gestation at which the monitoring was performed. Table 2 shows that there 
was an effect of gestation on the treatment effect on SBP (p<0.001); the drug 
effect decreased with advancing gestation. An effect of gestation on treatment 
effect on DBP was not observed. For HR we found a modest effect of 
gestation for patients treated with labetalol (p=0.046) but no effect on patients 
treated with nifedipine (Table 3). 
 
 SBP: p-value DBP: p-value 
Inhibitory   
  No inter-visit correlation (1)   
  Inter-visit correlation (2) 1 v 2 p<0.001 1 v 2 p<0.001 
  Type of Drug (3) 2 v 3 p=0.014  2 v 3 p=0.014 
Drug/Gestation interaction (4)  3 v 4 p<0.001  3 v 4 p=1 
 
Table 2. Going from model (1)-(4) involves increasing the complexity of the model by 
including an additional parameter to account for that extra information e.g. model (4) accounts 
for inter-visit correlation, type of drug and a drug/gestation time interaction.  
 
 HR:Labetalol: -2LL HR:Nifedipine: -2LL 
Inhibitory 
  No inter-visit correlation (1) 
 Condition failed 
Stimulatory   
  No inter-visit correlation (2) 
Condition failed  
Inhibitory 
  Inter-visit correlation (3) 
 
1 v 3 p=0.008 
Not applicable 
Stimulatory 
  Inter-visit correlation (4)  
Not applicable  
2 v 4 p<0.001 
Gestation (5) 3 v 5 p = 0.046 4 v 5 p=0.317 
 
Table 3. The -2*log-likelihood (-2LL) values for the model iterations, given in parentheses, for 
HR. Models (1) and (2) assess whether the inhibitor or stimulatory model best describes the 
data. Models (3) and (4) assess what effect inter-visit correlations has on model fit. Final 
model (5) assesses what effect gestation time has after accounting for inter-visit correlations. 
  
The models taken forward to assess time in target for SBP and DBP were 
model iteration number 3 in Table 2. Although for SBP we found that gestation 
did effect the treatment, the confidence intervals of the interaction term 
included zero.  This suggests the effect is highly uncertain and so a model 
without that interaction was taken forward.  
 
Time In Target 
To assess the clinical value of both drugs, time in target was determined.  For 
SBP we found that 80% of women spent the whole 8 hours within the target 
range (SBP<140mmHg) for both labetalol and nifedipine. For DBP, of the 
women on nifedipine 79% spent the whole 8 hours in target: 13% spent a 
proportion of time above target (DBP>99mmHg) and 8% were below target 
(DBP<80mmHg). In the labetalol group only 40% were in target during the 8 
hours. Although no woman on labetalol had a DBP>99mmHg, 60% of the 
women spent a varying proportion of the 8-hour window below the target 
range.  
  
Discussion 
 
This study has found a clinically significant difference in the BP lowering 
effects of labetalol and nifedipine MR. By using an indirect response model 
we were able to statistically compare the different effect of each drug on the 
BP as well as determining if there was any effect according to the individual or 
gestation. This is a relatively novel technique within the speciality partly 
attributed to the lack of pharmacodynamics research during pregnancy. 
Although this was an exploratory study and the results should be interpreted 
with caution, our findings suggest that nifedipine MR provides more stable 
day-time BP control, with less variation in BP over the dosing interval when 
compared to labetalol. In particular, significantly more women taking labetalol 
spent a larger proportion of time below the diastolic target compared to those 
taking nifedipine. 
 
Labetalol is a combined α1 and non-selective β adrenoreceptor antagonist 
with the ratio of α to β receptor potency about 1:3 for oral administration [11]. 
In our study labetalol had a relatively quick onset of action with a BP lowering 
effect seen by 2.5 hours post dose, the maximum effect being around 2.5 
hours for DBP and 4 hours for SBP. These findings correlate with an earlier 
study by Saotome et al. [11]. The BP lowering effect was short lasting and the 
BP had returned to baseline by 6.4 hours. These results suggest that the 
dosing interval of labetalol during pregnancy should be 6-hourly to achieve a 
consistent reduction in BP over time. Labetalol is known to produce a 
reduction in HR which is relative to the dose [12]. The simultaneous lowering 
in the pulse rate was seen in our study and demonstrates the more potent 
effects at the β-receptor. 
 
Nifedipine is a dihydropyridine derivative calcium channel blocker (CCB) that 
inhibits the influx of calcium through channels in smooth muscle resulting in 
vasodilation. It is known to produce a reflex tachycardia secondary to 
activation of the sympathetic nervous system [13]. An acute BP lowering 
effect of nifedipine MR was not seen for either SBP or DBP. This result was 
expected due to the longer duration of action and the fact that the women had 
  
usually taken a dose of nifedipine in the 12 hours prior to commencement of 
the monitoring which would still be exerting some effect. An increase in heart 
rate was noted in women who took nifedipine. 
 
A small double-blind randomized control trial comparing the acute effects of 
oral nifedipine and intravenous labetalol in a cohort of women with pre-
eclampsia also found opposing effects on HR [14]. In this study both drugs 
had a significant BP lowering effect by 60 minutes post dose. We did not see 
this acute effect in our nifedipine group; this may be explained by the high 
SBP (SBP>170mmHg) inclusion criteria in the previous study [14]. 
 
In the non-pregnant population beta-blockers have been found to increase BP 
variation [15], which has been linked to an increase in vascular events such 
as stroke and myocardial infarction independent of mean BP [16]. It has been 
suggested that the improved cardiovascular protection of CCBs compared to 
beta-blockers may be due to a reduction in the average BP in combination 
with a reduction in BP variability [17].  
 
Within the pregnant population, a small study by Maggioni et al. found DBP 
variation to be associated with FGR [18] which might contribute to the 
previously reported link between FGR and beta-blockers [19]. More recently 
secondary analysis of the BP variability in the CHIPS cohort found that 
increased variability (between clinic visits) resulted in more adverse maternal 
outcomes, but interestingly lower variability was associated with more adverse 
perinatal outcomes such as FGR and pre-term delivery [20].  
 
Blood pressure variability is not routinely considered in antenatal care but 
should be a focus of future work. Antihypertensive treatment targets should 
ideally include a reduction in BP variability as this, in combination with a 
reduction in mean BP, appears to be cardioprotective [21]. The finding that 
treatment with nifedipine resulted in reduced BP variability (compared to those 
on labetalol) in high-risk pregnant women concurs with previous effects 
reported in non-pregnant individuals. This study was not powered to 
determine whether a reduction in BP variability was associated with a 
  
difference in maternal or fetal outcomes; future work however, using the effect 
sizes determined by this study, could aim to address this important research 
question in women with CHT.  
 
Magee et.al found improved maternal outcomes with tighter BP control 
attributed to fewer episodes of severe hypertension [6]. We found no 
significant difference between labetalol and nifedipine on the SBP, however, a 
larger proportion of women in our study who were taking labetalol spent more 
time with their DBP<80mmHg compared to those on nifedipine MR. Due to 
earlier studies [5] concern with regards to running DBP too low may exist 
amongst obstetricians, therefore with its quicker onset of action labetalol may 
be better suited in the emergency setting when more rapid lowering of BP is 
desired. 
 
Pregnancy is known to affect the pharmacokinetics and pharmacodynamics of 
both drugs, but the available data is limited and the optimal dosing regime 
remains uncertain. Our data would suggest that a twice-daily dosing regime of 
labetalol would not be sufficient to maintain BP within target over a 24-hour 
period and further studies on optimal dosing frequency should be undertaken. 
 
This study has several limitations. The study was small and exploratory and 
included a clinically representative mixed cohort of women from different 
ethnic backgrounds, with different causes and severity of hypertension. Our 
study also relied on women accurately reporting time of drug ingestion. Lastly, 
the antihypertensive treatment in our cohort was not randomised. In the non-
pregnant population, treatment of hypertension is tailored according to 
ethnicity as this has been shown to impact on the efficacy [22]. Black patients 
when compared to white patients respond less well to beta-blocker 
monotherapy [23]. Knowledge of this may have resulted in preferential 
prescribing of nifedipine to black women in our study; however, the number of 
black women in each group was comparable. Furthermore, ethnicity is an 
important confounder that we were unable to adjust for due to the limited 
numbers. A feasibility study has recently been completed that supports a 
  
larger RCT to compare the efficacy of different antihypertensive medications 
in the different ethnic groups [24].   
 
Conclusion 
 
There are significant and important differences between the BP lowering 
effects of nifedipine and labetalol in pregnant women with CHT. Women 
taking nifedipine have a more stable daytime BP profile whereas those on 
labetalol spent a larger proportion of time with their DBP below 80mmHg. To 
date ABPM is not routinely used in the obstetric setting and clinicians 
frequently make management decisions based on single office BP 
measurements. Our study therefore has clinical implications; in addition to 
confirming the utility of ABPM, application of knowledge of the likely duration 
of BP lowering effects and the interpretation of BP readings accounting for 
drug ingestion time would substantially improve the dosing of 
antihypertensives in women with CHT in pregnancy. However, although the 
evaluation of BP lowering effects of these drugs is important, it is the overall 
effect on pregnancy outcome that is of paramount importance and currently 
this remains uncertain. A large RCT is required to investigate this further.  
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Abstract 
 
Aim 
To compare the blood pressure (BP) lowering effects of labetalol and 
nifedipine modified release (MR) in hypertensive pregnant women. We also 
investigated the effect on the heart rate (HR) and determined the proportion of 
time spent in target. 
 
Methods 
This was an exploratory study. Women with chronic hypertension taking either 
labetalol or nifedipine were offered 24-hour ambulatory blood pressure 
monitoring (ABPM). Sleep, wake and drug ingestion times were self-reported. 
An indirect response model was used to analyse the systolic BP (SBP), 
diastolic BP (DBP) and HR time-series; the effect of gestation and type of 
drug was evaluated. 
 
Results 
Forty-eight women were recruited: 24 in each group. There was no difference 
in clinical characteristics. In women taking nifedipine there was a positive 
association between the dose of nifedipine and pre-dose BP p=0.002, this 
was not present in the labetalol group. 
 
There was a difference between the drug effects on both the SBP and DBP 
time-series (p=0.014). In comparison to labetalol, there was less variation in 
day time BP in those women prescribed nifedipine. Women on labetalol spent 
a larger proportion of time with their DBP below target (<80mmHg). The HR 
dynamics were qualitatively different, a stimulatory effect was found with 
nifedipine compared to an inhibitory effect with labetalol.  
 
Conclusion 
There are significant and important differences between the BP lowering 
effects of nifedipine and labetalol. A large randomised control trial is required 
to investigate the relationship between BP variability and time in target on 
pregnancy outcomes. 
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Highlights 
 The blood pressure lowering effects are different between labetalol and 
modified release nifedipine 
 Labetalol has a quick onset of action that is short lasting 
 Nifedipine results in a more stable blood pressure profile 
 Ambulatory blood pressure monitoring can be successfully utilised in 
pregnancy and aids clinical decisions 
 
  
  
Table 1. Patient demographics and delivery outcome presented as either 
mean ± sd, N (%) or median (IQR)  
 
Figure 1. Panels A and B show a significant trend between the dose of 
nifedipine and pre-dose SBP and DBP values (p=0.002 for both). The plots in 
panels C and D demonstrate that there was no correlation for nifedipine 
between gestation at monitoring and the pre-dose SBP and DBP values 
(p=0.454 and p=0.196 respectively). Panels E and F show no trend between 
the dose of labetalol and pre-dose SBP and DBP values (p=0.710 and 
p=0.423 respectively). The plots in panels G and H show a lack of correlation 
for labetalol between gestation and pre-dose SBP and DBP values (p=0.091 
and p=0.056 respectively). 
 
Figure 2. Boxplots of the binned time-series data for pre-dose baseline values 
and subsequent time quartiles for SBP, DBP and HR. The box shows the 
inter-quartile range with the solid horizontal line within the box the median. 
 
Figure 3. SBP, DBP and HR values for labetalol (red open circles) and 
nifedipine (black open circles) after a single dose together with the mean 
simulation (solid lines).  
 
Table 2. Going from model (1)-(4) involves increasing the complexity of the 
model by including an additional parameter to account for that extra 
information e.g. model (4) accounts for inter-visit correlation, type of drug and 
a drug/gestation time interaction.  
 
Table 3. The -2*log-likelihood (-2LL) values for the model iterations, given in 
parentheses, for HR. Models (1) and (2) assess whether the inhibitor or 
stimulatory model best describes the data. Models (3) and (4) assess what 
effect inter-visit correlations has on model fit. Final model (5) assesses what 
effect gestation time has after accounting for inter-visit correlations. 
 
 
